Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study

Published:2016-04 Issue: Volume: Page:1921
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

aktas gokmen,Tulay Kuş,kalender mehmet emin,sevinc alper,camci celaletdin,kul seval

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review;Journal of Thoracic Disease;2021-06

2. Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients;Journal of Thoracic Disease;2020-03

3. FTIR spectra signatures reveal different cellular effects of EGFR inhibitors on nonsmall cell lung cancer cells;Journal of Biophotonics;2020-01-08

4. Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017;Lung Cancer;2019-05

5. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study;Cancer Chemotherapy and Pharmacology;2019-04-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP